In its most recent Pharmaceuticals and Healthcare report for Lebanon, Business Monitor International (BMI) issued a “cautiously optimistic” outlook for the market over the coming years. BMI believes that demand for high-value prescription drugs is driven by 3 factors: the government’s focus on facilitating access to healthcare services across the country, the rising disease burden (defined as the number of disability- adjusted life years lost to a disease in a particular country), and the high per capita healthcare spending. However, the upbeat outlook is hindered by the heavy influx of Syrian refugees, by rising violence in the region and by the political stagnation in the country.
According to BMI estimations, pharmaceutical sales in Lebanon reached $1.63B in 2015 and are expected to grow to $1.75B in 2016. Healthcare spending was estimated at $3.59B in 2015 and is also expected to rise to $3.91B in 2016.
To read the full report, click on the link below:
Pharmaceuticals and Healthcare in Lebanon – Numerous Opportunities to Explore